Search Results

Pierre Fabre Laboratories has been awarded the “Prix Galien International” Prize in the “Best Product for a Rare/Orphan Disease” category for EBVALLO®.

The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients* in Europe.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome.

Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require appropriate treatments.

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Pierre Fabre Laboratories announce the submission by Atara Biotherapeutics of Tabelecleucel Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA.

Pierre Fabre Laboratories announced the filing of an investigational new drug application to the U.S. Food and Drug Administration to initiate a first-in-human Phase I/II clinical trial with PFL-002/VERT-002 for solid tumors including non-small cell lung cancer.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).